Diabetalong - (Diabetalong) kuhikuhi i ka hoʻohana

Nā ʻōkuhi no ka hoʻohana:

Nā kumukūʻai ma nā lāʻau lapaʻau pūnaewele:

Diabetalong he huahe o ka sulfonylurea o ka lua o ka hanauna, kahi lāʻau hypoglycemic no ka hoʻoponopono waha.

E hoʻokuʻu i ke ʻano a me ka ʻano

Ka hana ʻai - nā papa hoʻokele i hoʻolaʻa ʻia (60 mg) a me nā papa hoʻokuʻu i hoʻihoʻi ʻia (30 mg): flat-cylindrical, kokoke ke keʻokeʻo a ʻūhā paha, me kahi bevel, ʻae ʻia nā kelepona, 60 mg nā papa ʻōpala, me kahi laina hoʻokaʻawale (ma ka contour pulima papa: 60 mg kēlā me kēia - 10 mau p., i kahi pūnoho kāleka 1, 2, 3 a i ʻole 6 kīʻaha, 20 pcs., i loko o kahi ake kāleka 1, 3, 5 a i ʻole 6 mau pā, 30 mg - 10 pcs., i ka pūkaʻina pahu pepa o 3 a 6 mau ʻeke paha).

Pākaukau 1 papa:

• mea waiwai: gliclazide - 60 mg a 30 mg,
• Nā mea kōkua: aerosil (colloidal silicon dioxide), calcium stearate, 80 papa (lactose monohydrate), hypromellose (Metocel K-100 LV CR Premium), talc.

Eia kekahi, ma nā papa me ke hoʻokuʻu ʻia i ka lōʻihi o ka hoʻonohonoho ʻana o kahi hypromellose - Metolosa 90 SH-100SH.

Nā hōʻailona no ka hoʻohana ʻana

Hoʻohana ʻia ka hoʻohana ʻana o Diabetalong no ka mālama ʻana i ka mellitus type type 2 i ka loaʻa ʻole o ka hopena o kaʻai ʻana i ka lāʻau, hana kino a me ke kaumaha.

Eia kekahi, ua kau ʻia nā papa hoʻokuʻu i hoʻihoʻi ʻia no ka pale ʻana i ka hoʻopiʻi ʻana i ka maʻi mellitus i mea e hōʻemi ai i ka hopena o ka hoʻomohala ʻana i ka retinopathy, nephropathy, kaʻi myocardial, kaʻi ʻana ma o ka mana glycemic control i ka diabetes type 2.

Nā Hoʻohui

• maʻi diabetes type 1
• maʻi maʻamau ketoacidosis, maʻi kanesa, preca maʻi maʻi,
• hui pū me ka miconazole,
• maʻi hepatic koʻikoʻi a / a i ʻole kauliki,
• wā hāpai
• hana waiū
• makahiki i 18 makahiki
• lactase hema loa, glucose-galactose malabsorption syndrome, lolika lactose,
• ka manawa like o ka phenylbutazone a i danazole,
• hypersensitivity i sulfonamides, nā derivatives sulfonylurea, nā mea o ka lāʻau.

Me ka makaʻala, pono e kuhikuhi i ka maʻi Diabetalong i nā mea maʻi me ka nutrular nutritional a me / a i ʻole ke kaupaona ʻana, ka nele o ka glucose-6-phosphate dehydrogenase, nā maʻi koʻikoʻi o ka pūnaehana cardiovascular (me ka maʻi naʻau coronary, atherosclerosis), hypopituitarism, hypothyroidism, adrenal insufficiency a i ʻole / a i ʻole hemahema ka hoʻohana ʻana, hoʻohana lōʻihi no ka glucocorticosteroids, e hōʻeha ana i ka ʻaloʻaka, i ka wā ʻelemakule.

ʻLoe a me ke kākele

Lawe ʻia nā papa papa me ka ʻōlelo maoli, ʻoi loa i ka wā o ka ʻaina kakahiaka, 1 mau lā i kēlā lā.

Pono e hoʻoholo ʻia ka nui o ka lāʻau e ke koho, i ka ʻike ʻana i ka kū hoʻokahi o ka glucose a me ka hemoglobin glycosylated i loko o ke koko.

1 papa o 60 mg e like me ka hopena o ka therapeutic o 2 papa o 30 mg. ʻO ka hoʻokaʻawale ʻana i nā pilikia ma nā papa he 60 mg e ʻae, inā pono, e hoʻokaʻawale iā ia i ʻelua māhele. Inā loaʻa ia kahi hapa o ka papa i lawe ʻia, ʻaʻole pono e lawe.

Manaʻo ʻia i kēlā me kēia lā: ʻo ka pawaʻu mua (me nā mea maʻi ʻoi aʻe ma lalo o 65) he 30 mg, me kahi pane kūpono e hoʻohana ʻia ana he ʻano mālama mālama ʻia. I ka hana ʻole o ka mana glycemic lawa, pono i ka hopena o kēlā me kēia lā (ʻaʻole iʻoi aku ma mua o 1 manawa i nā wiki 4) i hoʻonui ʻia i 60, 90 a 120 paha mg. Inā ʻaʻole e hōʻemi ka ʻemi o ka hōʻemi o ka glucose i ke koko ma hope o 2 mau hebedoma e lawe i nā papa, a laila hoʻonui ka nui i ka lolo ma kahi he 2 mau pule.

Mai hana i kahi kiʻekiʻe kiʻekiʻe ma hope o ka hoʻoliki ʻana i hoʻokahi mau momona.

ʻO ka dosis kiʻekiʻe loa i kēlā me kēia lā he 120 mg.

Ke hoʻololi nei mai kahi lawehala hypoglycemic waha, ʻo kona kumukūʻai a me ka hapalua hoʻi ke ola e pono i ka mooolelo.

Inā he hapa lōʻihi ka ola o ka huahana o mua o ka olony sulfonylurea, ua makemake ʻia e hoʻomaha i kekahi o nā helu i mua o ka lawe ʻana i ka lāʻau. Hōʻalo kēia i ka hypoglycemia kūʻē i ke kua o ka hopena o ka hopena hoʻohui o ʻelua mau mea hoʻohālikelike hypoglycemic. I loko o kekahi mau pule, koi ʻia ka nānā ʻana i ka pae o ka glucose koko.

Pono ka dosis hou o ka maʻi Diabetalong e 30 mg.

Hōʻike ʻia nā papa i hui pū ʻia me nā mea hana hypoglycemic e like me biguanides, alpha glucosidase inhibitors a i ʻole insulin.

ʻO nā maʻi me ka maʻi palaualelo o ke kala ʻole i ke kaumaha maʻalahi i kuhikuhi ʻia i kahi ʻano maʻamau o ka lāʻau lapaʻau, akā pono e mālama ʻia ka lāʻau lapaʻau ma lalo o ka mākaʻi olakino kokoke.

No ka mea, ʻo ka poʻe maʻi me ka kīnā ʻole o ka palaka a i ʻole ke kaupaona ʻana, ka hopena a i ʻole ka hoʻopaʻi ʻana i ka hopena o ka endocrine (hypothyroidism, pituitary a me adrenal insufficiency), nā pilikia nui o ka pūnaehana cardiovascular (maʻi coronary heart, ka atherosclerosis maʻamau, carotid arteriosclerosis) a i ʻole hoʻi i ke oki ʻana i ka hopena lōʻihi a / a me ka therapy i nā kiʻekiʻena kiʻekiʻe, ua pilikia ka glucocorticosteroids i ka hoʻomohala ʻana i ka hypoglycemia, pono lākou e kuhikuhi ʻia aku i ka 30 mg o ka lāʻau lapaʻau i kēlā me kēia lā.

No ka pale ʻana i nā hoʻopiʻi o ka maʻi mellitus i ka manawa o ka hoʻohana ʻana i ka lāʻau lapaʻau, pono nā mea maʻi e hahai i nā meaʻai e ʻae ʻia e ke kauka, hana mau i nā hoʻomaʻamaʻa kino, a inā pilikia nā ʻano, e nīnau koke i kahi kauka.

Nā hopena hopena

• hoʻomohala ʻana i ka hypoglycemia: nā hōʻailona - ka pōloli nui, nui ka luhilahi, nāwaliwali, ka ʻili ala, ka ʻeha, ka puhipuhi, ka luaʻi, ka nui ʻana o ka momona, ka huhū, ka haunaele, ka hoʻomāhuʻaka, pane pane, hoʻemi i ke kūpaʻa, ke kaumaha, ka maʻiʻike a me ka haʻi ʻana , ka aphasia, pīhoihoi, ka manaʻo hopohopo, ka paresis, ka nalowale ʻana o ka hoʻopaʻa ʻana iā ia iho, ʻike ʻole ʻia, hopohopo, ke hiamoe nei, bradycardia, delirium, hāpau ka papau, nā koi, hoʻoweliweli, tachycardia, hoʻonui nui aʻe ka uʻeha, arrhythmia, angina pectoris, palpitations, nalowale o ka ʻike, coma, make,
• mai ka ʻōpū o ka gastrointestinal: nausea, ka luaʻi, ka ʻōpū o ka ʻōpū, ʻīwī, ke kīnā
• nā hana dermatological: itching, lapalapa ʻili, urticaria, erythema, edema Quincke, rula maculopapular, ʻāhewa nepholysis epidermal, ʻĀhane Stevens-Johnson,
• mai nā ʻōnaehana hematopoietic a me nā ʻōnaehana lymphatic: transient hematological disorders - leukopenia, anemia, thrombocytopenia, granulocytopenia,
• mai ka ʻōnaehana hepatobiliary: hana nui o ka phosphatase alkaline, aspartate aminotransferase (ACT), alanine aminotransferase (ALT), i nā hihia luhi - hepatitis, jaundice cholestatic,
• mai nā naʻau sensory: nā hana ulu ʻelele (ʻoi aku ka pinepine ma ka hoʻomaka ʻana i ka maʻi),
• nā mea ʻē aʻe: hiki (nā hopena maʻamau no ka derony o ka sulfonylurea) - kahi o ka nui o ka hana ole, agranulocytosis, erythrocytopenia, hemolytic anemia, alecas vasculitis, pancytopenia, hyponatremia.

Nā ʻōlelo kikoʻī

E kūʻē i ke kūmole o ka hoʻohana ʻana o Diabetalong, a me nā derivatives sulfonylurea ʻē aʻe, aia kahi hopena o ka hypoglycemia. I mea e hoʻopau ai i kāna mau hōʻailona, ​​pono koke ka mea maʻi e lawe i kekahi huahana momona e loaʻa ana (ke kō (hiki ke kō), ʻaʻole kūlea ka kō.

Ma ka hihia o ka pilikia a me ka lōʻihi o ka hypoglycemia, pono ka mea maʻi i ka hoʻokipa a me ka hoʻokele intravenous o kahi hopena dextrose no nā lā he nui.

Ke koho ʻana i ka lāʻau lapaʻau, pono e ʻike ʻia ka mea maʻi a me nā ʻohana o ka ʻohana e pili ana i ka pono o ka hoʻokipa ʻana i ka ʻai maʻamau, ʻo ia hoʻi i ka ʻaina kakahiaka, nā pōpilikia a me nā hōʻailona o ka hypoglycemia, me nā ʻano kūpono i kona hoʻomohala ʻana. Ma muli o kaʻai ʻole, ʻae ʻole a i ʻole ka lolo kino-ʻoi aku ka nui o ka ʻai me ka hypoglycemia, koʻikoʻi loa ia e hahai i nā ʻōlelo a ke kauka a pau.

Ma waho aʻe o kahi kīʻaha haʻahaʻa, ʻohi pinepine ʻia ka hypoglycemia e ka hoʻoikaika kino a ikaika loa paha, ka inu ʻana i ka wai ʻona, a i ʻole ka lawe ʻana i nā lāʻau hypoglycemic i ka manawa like.

Pono e hali i ka manaʻo i ka hiki ke hoʻomohala i kahi hōʻemi o ka hypoglycemia ma hope o kahi kūleʻa maikaʻi o ia mea.

E pili ana nā kumu aʻe i ka hoʻonui ʻia o ka pilikia o ka hypoglycemia:

• i ka hoʻoluhi a ka mea maʻi a hiki ʻole (ʻoi aku ka maʻamau o ka makahiki kiʻekiʻe) e mālama i kona kūlana a hahai pono i nā ʻōlelo a ke kauka,
• kūlike ʻole me ka hoʻopaʻi a me ka meaʻai,
• ka pale hewa ʻana o ka kaulike ma waena o ke kauā ʻana o nā mea kālai a me ka hana kino,
• ka hana like ʻana o nā lāʻau lapaʻau e hoʻoikaika ai i ka hopena hypoglycemic o ka lāʻau lapaʻau,
• uhaiki pohihihi
• nā mālamalama maikaʻi ʻole
• ke ʻano o ka nui o ka momona thyroid, ka adrenal a me ka lawa pituitary,
• overdose o Diabetalong.

ʻO ka loli i loko o ka pharmacokinetic a / a i ʻole nā ​​huahana pharmacodynamic o gliclazide i nā mea maʻi me ka maʻi emal a me ka hepatic i hopena maikaʻi i ka paʻakikī o ka hypoglycemia i ka hanana o kona hoʻomohala.

Manaʻo ʻia e lawe i ka lāʻau lapaʻau me ka mālama ponoʻī ʻana i ke kaʻe o ka glucose koko.

Me ka nele o ka dehydrogenase glucose-6-phosphate, hiki i ka lāʻau lapaʻau ke kōkua i ka hoʻomohala ʻana o ka anemia hemolytic, no laila e noʻonoʻo pono ana e noʻonoʻo i ka hiki ke hoʻopuka ʻana i kahi aelike hypoglycemic o kekahi hui.

Ma ka hihia o kahi maʻi ʻeha a nui paha ka hoʻomaʻamaʻa ʻana, pono e noʻonoʻo ʻia i ka hiki ʻana o ka hoʻomau ʻia ʻana o ka lāʻau lapaʻau me ka hoʻonoho ʻana i ka insulin.

ʻO ke kumu no ka lawe ʻana i ka hopena ma o ka hopena hypoglycemic o Diabetalong ma hope o ka hoʻohana lōʻihi ʻana, ʻo ia paha ka emi o ka pane ʻana i ka hopena therapeutic a me ka holomua o ka maʻi. Ke hōʻike nei i ka pale ʻana o ka lāʻau lapaʻau kūloko, pono e loiloi ke kauka i ka lawa o ka nui i lawe ʻia e ka mea maʻi a hōʻoia i ka ʻai ʻana ma ka meaʻai.

ʻO ka lawe ʻana i ka lāʻau lapaʻau i ka wā o ka ʻaina i hōʻemi ʻia ka hopena o ka hopena mai ka gastrointestinal tract.

Ma ka hōʻeha kaumaha a me / a i ʻole ka hopena ʻole, ua hōʻike ʻia ka mea maʻi e hoʻohana i ka insulin.

Ke hoʻolālā nei i kahi hāpai a i ʻole ke kuhi ʻana i ka wā e lawe nei i ka lāʻau lapaʻau, tūtū ʻia kahi wahine e hoʻololi i ka insulin therapy.

Hāʻawi ʻia i ka pilikia o ka hypoglycemia, ua ʻōlelo ʻia nā mea maʻi e hoʻomaʻamaʻa inā ka hoʻokele ʻana i nā kaʻa a me nā mākaʻi i ka wā e hoʻohana nei i ka lāʻau.

Hoʻohui nūhou

Me ka hoʻohana ʻana i ka maʻi Diabetalong:

• Hoʻonui nui ka miconazole i ka hopena o ka gliclazide,
• me ka hoʻokele systemic, phenylbutazone paipai i ka ka haʻalele ʻana o ka gliclazide mai kona hui ʻana me ka protein plasma a / a i ʻole ka lohi i kona ʻoliʻī mai ke kino, e hoʻonui ana i ka hopena hypoglycemic o ka lāʻau lapaʻau,
• e hoʻonui ai i ka ethanol (me ka waiʻona a me ka huaʻai e pāʻina) ka nui o ka hypoglycemia, hiki ke hana i ka hypoglycemic coma.
• nā hana āpau hypoglycemic ʻē aʻe (insulin, acarbose, metformin, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists), beta-blockers, fluconazole, angiotensin-hoʻohuli i ka hoʻohui o nā enzyme (captopril, blocktopril, ectopril)₂- nā mea i hoʻopaʻaʻia histamine, monoamine oxidase inhibitors, sulfonamides, clarithromycin, non-steroidal anti-inflammatory drug - hoʻonui i ka hopena hypoglycemic o ka lāʻau a me ka hopena o ka hypoglycemia,
• He hopena maʻi diabetes ka Danazole, e hōʻemi ana i ka hopena hopena o ka lāʻau lapaʻau,
• ʻO Chlorpromazine i kahi kaʻe ma luna o 100 mg i kēlā me kēia lā, hōʻemi i ka mea huna o ka insulin, e hoʻonui i ka kaila o ka glucose i loko o ke koko,
• ʻO ka tetracosactides a me ka glucocorticosteroids no ka hana systemic a me ka topical e hoʻonui i ka kao o ka glucose i loko o ke koko, hiki ke hōʻemi i ka hoʻohaʻahaʻa kalama a waiho i ka hoʻomohala ʻana o ka ketoacidosis,
• salbutamol, ritodrin, terbutaline no ka hoʻokele intravenous e hoʻonui i ka kiʻekiʻe o ka glucose i loko o ke koko,
• hiki ke hoʻonui i ka hopena o ke warfarin a me nā mea anticoagulants.

Nā hui Diabetalong e: Diabinax, Gliclazide MV, Gliclazide-Akos, Glidiab MV, Diabeton MV, Glucostabil.

Ka hana lāʻau lapaʻau

ʻO ka lāʻau lapaʻau hypoglycemic Oral, kahi derony o ka sulfonylurea o ka lua o ka hanauna.

Hoʻonui ia i ka mea huna o ka insulin i ka pancreas, hoʻohaʻahaʻa i ka pae o kaʻae i loko o ke koko, hoʻonui i ka hopena o ka insulin-secretory o ka glucose a hoʻonui i ka paʻakikī o nā ʻiʻo peripheral i ka insulin. Ma hope o 2 mau makahiki o ka mālama ʻana, ʻaʻole nui ka poʻe maʻi e hoʻomohala i ka lāʻau (hoʻonui i nā pae o ka insulin postprandial a me ka huni ʻana o C-peptides i noho).

Hoʻololi i ka manawa manawa mai ka manawa o ka ʻai ʻana a i ka hoʻomaka ʻana i ka huna ʻana i ka insulin. Hoʻihoʻi hou i ka makamua o ka loaʻa ʻana o ka inikua o ka insulin i ka pane ʻana i ka intake glucose (like ʻole me nā derivatives sulfonylurea ʻē aʻe, he hopena nui ia ma ka lua o ke ʻano o ka honi ʻana). Hoʻonui ʻia ia i ka lua o ka neʻe o ka hana huna o ka insulin. Hoʻemi i ka punaha o ka hyperglycemia ma hope o ka ʻai ʻana (a hoʻemi i ka hyperglycemia postprandial).

Hoʻonui ʻo Glyclazide i ka mahele o ke kino peripheral i insulin (i.e., he hopena i hoʻihoʻi ʻia i ka extrapancreatic). I ka kiko o ka ʻiʻo, ka hopena o ka insulin i ka uptake glucose, ma muli o ka hoʻomaikaʻi ʻana o ke ʻano maʻi i ka insulin, i hoʻonui nui ʻia (a i + 35%), ʻoiai ka mea e hoʻoulu ai ka glycazide i ka hana o ka glycogen synthetase.

Hoʻēmi i ka hana o ka glucose i loko o ka ate, ka hoʻomaʻamaʻa ʻana i nā kūlā glucose wikiwiki.

Hoʻopili i nā mea pili i ka metabolism, hiki ke hoʻonui ka gliclazide i ka microcirculation. Ke hōʻemi nei ka lāʻau lapaʻau i ka hōʻemi o ka trombosis hoʻokahe koko liʻiliʻi, e pā ana i nā hana ʻelua i hiki ke komo i ka hoʻomohala ʻana i ka hoʻopiʻi ʻana i ka maʻi mellitus. hana dibrinolytic o vascular endothelium a me ka hoʻonui ʻana i ka hana o ke kiko plasminogen activator.

Loaʻa i ka Glyclazide nā mea antioxidant: e hōʻemi ana i ka pae o lipid peroxides i loko o ka plasma, e hoʻonui ai i ka hana o ke kaila o ke koko reddroid dismutase.

Ma muli o nā mea kakaʻina o ka ʻano dosage, ʻo kahi papa i ka lā i kēlā me kēia lā o ka papa Diabetalong ® 30 mg e hāʻawi ana i ka hopena therapeutic koʻikoʻi o gliclazide i loko o ke koko koko no 24 mau hola.

Lapaʻau lāʻau

Ma hope o ka lawelawe waha, ua hoʻopiha piha loa ʻia ka gliclazide mai ka ʻāpana kūwili. ʻAʻohe ʻai i ka ʻai ʻana. Ke hoʻonui mālie nei ka ʻike ʻana o ka mea hana i ka plasma koko, a hiki i ka nui a hiki i ka pā poli 6-12 mau hola ma hope o ka lawe ʻana i ka lāʻau. He haʻahaʻa loa ka ʻano o ka wae ʻana. ʻO ka pilina ma waena o ke ʻano a me ka neʻe o ka lāʻau lapaʻau ma ka kaila koko he linear hilinaʻi i ka manawa i ka manawa.

ʻO ka wahī a me ka metabolism

ʻO ka pilina o ka protein plasma e pili ana i ka 95%.

Hoʻonohonohoʻia ia i loko o ka ate a hoʻopili i ka nui o nā keiki. ʻAʻohe huahana metabolites ikaika i loko o ka plasma.

Lawe ʻia ka hana e nā keiki ma ke ʻano o ka metabolites, ʻoi aku ka liʻiliʻi o 1% o ka lāʻau i ka excreted i loli ʻole.

T 1/2 e pili ana i 16 hola (12 i 20 mau hola).

ʻO ka pharmacokinetics i nā hihia lapaʻau kūikawā

I ka poʻeʻelemakule, ʻaʻohe i nānā ʻia nā hoʻololi koʻikoʻi i loko o nā pānaʻi pharmacokinetic.

Ka hoʻoponopono ʻia ʻana

Ke koho ʻia ka lāʻau lapaʻau wale nō no ka mālama ʻana i nā pākeke.

ʻO ka Diabetalong ® 30 mg mau hoʻololi i hoʻokuʻu ʻia e lawe ʻia ma nā lā he 1 i ka lā / lā i ka wā kakahiaka.

No nā poʻe maʻi i loaʻa ʻole ma mua o ka lawaiʻa (me ka poʻe no ka ʻoi aku ma mua o 65 mau makahiki), ʻo ka dosis mua he 30 mg. A laila koho ʻia ka pākuhi kū hoʻokahi a hiki i ka hopena hopena i makemake ʻia.

Pono e hoʻokau ʻia ka maʻi ʻaina e like me ka pae o ka glucose i ke koko ma hope o ka hoʻomaka ʻana o ka mālama ʻana. ʻO kēlā me kēia loli ka hopena i hoʻopaʻa ʻia ma hope o ʻelua mau pule ʻelua.

Hiki i ka palena o kēlā me kēia lā nā loli mai 30 mg (1 tab.) A 90-120 mg (mauʻu 3-4.). ʻAʻole pono nā lā o kēlā me kēia lā e 120 mg (4 papa).

Hiki i ke Diabetalong ® ke hoʻololi i nā papa gliclazide maʻamau maʻamau (80 mg) i loko o nā papa o 1 i 4 papa / lā.

Inā poino ʻoe i hoʻokahi mau helu a i ʻole paha ka lāʻau lapaʻau, ʻaʻole hiki iā ʻoe ke lawe i kahi kiʻekiʻe kiʻekiʻe ma kahi aʻe (i ke kakahiaka aʻe).

Ke hoʻololi nei i kekahi lāʻau lapaʻau hypoglycemic hou me nā papa Diabetalong ® 30 mg, ʻaʻohe pono o ka manawa transitional. Pono ʻoe e haʻalele i ka ʻai i kēlā me kēia lā i kekahi lāka hou aku a i ka lā aʻe e hoʻomaka i ka lawe ʻana i kēia lāʻau lapaʻau.

Inā loaʻa i ka mea maʻi ka hopena me ka sulfonylureas me ka hapalua hapalua, a laila e nānā pono ana (ka nānā ʻana o ka glucose koko) no nā hebedoma 1-2 pono e pale ai i ka hypoglycemia ma muli o ke ʻano o nā hopena i koe o ka hopena ma mua.

Hiki ke hoʻohana i ka Diabetalong ® i hui pū me ka biguanides, alpha-glucosidase inhibitors a i ʻole insulin.

I ka poʻe maʻi me ka leʻaleʻa a me ke kaulike ʻole o ka renal, ʻōlelo ʻia ka lāʻau i loko o nā koina like ʻole e like me i nā mea maʻi me ka hana maʻamau maʻamau. I nā hana hoʻokalakino nui, contraindicated ʻo Diabetalong ®.

I nā mea maʻi i ka hopena o ka hoʻomohala ʻana i ka hypoglycemia (ʻaʻole i lawa a i ʻole ke kaupaona ʻana, ka hōʻeha a i ʻole ka hoʻopaʻi ʻana i ka hopena o ka endocrine i loko o ka maʻi - hipuitary a me adrenal insufficiency, hypothyroidism, hiki ke hoʻopau ʻia i nā glucocorticosteroids ma hope o ka lōʻihi a / a i ʻole ka hoʻoponopono ʻana i ka nui, nā maʻi koʻikoʻi o ka ʻōnaehana cardiovascular system / IHD koʻikoʻi, ʻo ka carotid arteriosclerosis, ākea nui o ka atherosclerosis /) ua kauoha ʻia e hoʻohana i ka palena haʻahaʻa (30 mg 1 manawa / lā) o ka lāʻau maʻi Diabetalong ®.

Loaʻa ka hopena

ʻO ka hypoglycemia (i ka hana hewa ʻana o ka nohona hōʻano a me ka ʻai ʻole): ka ʻeha, ka nui o ka momona, ka pōloli, ka nui ʻana o ka luhiluhi, palupalu nui, palpitations, arrhythmia, piʻi nui ke koko, ka hiamoe, insomnia, ka hoʻohaunaele, ka huhū, ka hopohopo, irritability, hoʻonaninani, ʻike ʻole. hoʻokūkū a lohi i ke kūpaʻa, ke kaumaha, ʻike maka, aphasia, pāhuhi, paresis, hōʻano luhi, dizziness, ʻoluʻolu o ka hōʻoluʻolu, ka lilo ʻana o ka pale ponoʻī, delirium, hoʻopaʻapaʻa, superficial E ka hanu, bradycardia, unconsciousness, coma.

Mai ka pūnaehana hana ʻana: ka puki, ka luaʻi, ka ʻeha, ka ʻeha o ka ʻōpū, constipation (ke ʻano o ka hōʻeha ʻana o kēia mau ʻōpana i ka wā i lawe ʻia me ka meaʻai), ʻano liʻiliʻi - hana i ka hana hepa (hepatitis, hoʻonui i ka hana hepatic transaminases, alkaline phosphatase, jaundice cholestatic - koi i ka hoʻihoʻi ʻana i ka lāʻau).

Mai nā ʻōpū hemopoietic: mālama ʻia o ka hematopoiesis o nā iwi (anemia, thrombocytopenia, leukopenia, granulocytopenia).

He maʻi kūlohelohe: ʻeha ʻili, urticaria, loko o ka ʻili, komo maculopapular a bullous), erythema.

ʻO nā mea'ē aʻe: ʻike maka.

ʻO nā hopena maʻamau o nā derivatives o ka sulfonylurea: erythropenia, agranulocytosis, anemia hemolytic, pancytopenia, vasculitis alerine, hoʻoweliweli ma ka hopena o ke ola.

ʻŌpū a me ka lactation

ʻAʻoheʻike me kahi gliclazide i ka wā hāpai. ʻAe ʻia ka ʻikepili ma ka hoʻohana ʻana i nā derivatives sulfonylurea i ka wā hapai.

I nā haʻawina ma nā holoholona holoholona, ​​ʻaʻole i ʻike ʻia nā hopena teratogenic o gliclazide.

No ka hōʻemi i ka hopena o ka malenation malenital, pono ka hoʻokele (kūpono pono i ka maʻi maʻi) o ka maʻi mellitus.

ʻAʻole hoʻohana ʻia ka lāʻau hypoglycemic oral i ka wā hāpai. ʻO ka lāʻau lapaʻau i koho no ka mālama ʻana i ka maʻi maʻi i nā wāhine hāpai i ka insulin. Ke paipai ʻia e pani i ka waiwai o ka lāʻau hypoglycemic waha me ka hoʻōla ʻana o ka insulin i ka wā i hāpai ʻia ai kahi hapaha hoʻolālā, a inā inā loaʻa ka hānau ʻana i ka wā e lawe nei i ka lāʻau.

Ke noʻonoʻo nei i ka hapa ʻole o nā ʻike i ka waiwai o ka gliclazide i ka umauma umauma a me ka hopena o ka hoʻouluʻana i ka hypoglycemia neonatal, ka umauma o ka maʻi o ke kūleʻa ʻana i ka wā o ka lāʻau lapaʻau.

Ke keu

Nā hōʻailona: hypoglycemia, ʻike hemahema, hypoglycemic coma.

Hana: inā ʻike ka mea maʻi, lawe i ke kō i loko.

ʻOi paha ka hoʻomohala ʻana i nā kūlana hypoglycemic koʻikoʻi, ka hele pū ʻana me ka coma, kaʻaila a i ʻole nā ​​ʻano neurological ʻē aʻe. Inā ʻike ʻia kēlā mau hōʻailona, ​​pono ka mālama olakino a me ka haukapila koke ʻia.

Inā kānalua a hopu ʻia paha ka comog hypoglycemic, he 50 ml o ka hopena o 40% dextrose (glucose) i hoʻopaʻa koke ʻia i ka mea maʻi. A laila, ke mālama ʻia kahi hopena o 5% dextrose (glucose) i mea e mālama ai i ka pae o ka glucose i loko o ke koko.

Ma hope o ka ʻike hou ʻana, pono e hāʻawi i ka mea ʻai i ka mea maʻi i ka momona hoʻokaʻawale ʻia (i mea e pale ʻole ai ka hana hou o ka hypoglycemia). ʻO ka mālama pono ʻana i nā pae hāhā o ke koko a me ka nānā ʻana o ka mea maʻi e lawe ʻia aku ma kahi o 48 mau hola ma hope. Ma hope o kēia manawa o ka manawa, e pili ana i ke ʻano o ka mea maʻi, ua hoʻoholo ke kauka komo i ka pono no ka nānā hou.

ʻAʻole kūleʻa ʻia ʻo Dialysis ma muli o ka hoʻopio ʻana i ka gliclazide i nā protein plasma.

Ka hoʻonohonoho ʻana a me ke ʻano o ka hoʻokuʻu ʻana

Nā Papa - 1 papa:

Nā mea waiwai: glyclazide - 30 mg, Pūnaewele: hypromellose (Metocel K-100 LV CR Premium), colloidal silicon dioxide (aerosil), calcium stearate, talc, lactose monohydrate (80 mau papa).

ʻO ka moliki hypoglycemic Oral, kahi derony o ka sulfonylurea o ka lua o ka hanauna. Hoʻokomo i ka mea huna o ka insulin e β-cells o ka pancreas. Hoʻonui i ka paʻakikī o nā kōpili peripheral i insulin. Ka mea i hāpai, ke hoʻoikaika nei i ka hana o nā enzyme intracellular (ma ke kikoʻī, ʻo ka muscle glycogen synthetase). Hoʻololi i ka manawa manawa mai ka manawa o ka ʻai ʻana a i ka hoʻomaka ʻana i ka huna ʻana i ka insulin. Hoʻihoʻi i ka mua o ka neʻe o ka huna ʻana o ka insulin, e hoʻēmi ana i ka hopena o ka postprandial o hyperglycemia.

Hoʻololi ʻo Glyclazide i kahi hoʻopili platelet a me ka hoʻohui ʻana, e hoʻolohi ana i ka hoʻomohala ʻana o kahi trombus parietal, a hoʻonui i ka hana vibr folyinolytic. Hoʻohālikelike i ka hoʻokele vascular. Loaʻa ia ia nā waiwai anti-atherogenic: e hoʻohaʻahaʻa ana i ke kahe o ke kolamu o ka nui (Ch) a me LDL-C i ke koko, hoʻonui i ke kahe o HDL-C a hoʻemi hoʻi i ka nui o nā radical manuahi. Kāohi i ka hoʻomohala ʻana o ka microthrombosis a me atherosclerosis. Hoʻomaikaʻi i ka microcirculation. Hoʻēmi i ka maʻi maʻi vascular i ka adrenaline.

Me ka nephropathy maʻi maʻi me ka hoʻohana lōʻihi ʻana o ka gliclazide, ua ʻike ʻia kahi emi nui i ka proteinuria.

Ma hope o ka lawelawe waha, ua hoʻoiho koke ʻia mai ka digestive tract. Loaʻa ka C max i loko o ke koko a ma kahi o 4 mau hola ma hope o ka lawe ʻana i hoʻokahi kope o 80 mg.

ʻO ka pilina protein Plasma he 94.2%. V d - e pili ana iā 25 l (0.35 l / kg kino kino).

Hoʻomau ia i ka puʻuwai me ka hoʻokumuʻana o 8 mau metabolites. ʻAʻohe huakaʻi koʻikoʻi kahi hopena hypoglycemic, akā kahi hopena ma ka microcirculation.

Nā hola T1 / 2-12. Hoʻopili nui ʻia e nā ʻōpū ma nā ʻano o nā metabolites, emi mai ma kahi o 1% e hoʻopiʻi ʻia i ka urine i loli ʻole.

ʻO ka lāʻau lapaʻau hypoglycemic oral.

Hoʻohana ʻia ka Gliclazide e mālama i ka mellitus non-insulin-hilinaʻi i hui pū me ka meaʻai haʻahaʻa-calorie.

I ka wā mālama, pono ʻoe e kiaʻi pono i ka pae o ka glucose i loko o ke koko ma kahi ʻōpū ʻole a ma hope o ka ʻai ʻana, nā ʻano o nā lā i kēlā me kēia lā i ka glucose.

Ma ka hihia o nā mea hōʻiliʻili aiʻole nā ​​decompensation o ka maʻi mellitus, pono ia e noʻonoʻo i ka hiki ke hoʻohana i ka hoʻomākaukau ʻana i ka insulin.

Me ka hoʻomohala ʻana o ka hypoglycemia, inā ua ʻike ka mea maʻi, ua hoʻokaʻina (a i ʻole kahi hoʻoponopono o ke kō) paha i loko. I ka hihia o ka nalowale o ka ʻike, intravenous glucose a i ʻole glucagon sc, intramuscularly a i ʻole intravenously e lawelawe. Ma hope o ka loaʻa hou ʻana i ka naʻauao, pono e hāʻawi i ka mea maʻi i ka momona o ka mea laʻa i mea e pale ai i ka hoʻomohala hou ʻana o ka hypoglycemia.

Me ka hana like o ka gliclazide me ka verapamil, koi ʻia ka nānā ʻana i nā pae glucose i ke koko, me ka acarbose, ka nānā akaʻa ʻana a me ka hoʻoponopono ʻana i ka paukū dosage o nā hana hypoglycemic e koi ʻia.

ʻAʻole ʻōlelo ʻia ka hoʻohana pinepine ʻana o gliclazide a me cimetidine.

Hoʻopau i nā Papa Hoʻohui, 30 mg

Aia ma ka papa papa

ʻO ka mea kūlohelohe he gliclazide - 30 mg,

nā mea waiwai: hypromellose, colloidal silicon dioxide, calcium stearate, talc, lactose monohydrate

Ke keʻokeʻo a kokoke paha keʻokeʻo paha nā papa, ʻeleʻele-cylindrical, me kahi bevel. ʻAe ʻia ka "marbling"

ʻO nā waiwai Pharmacological

Ma hope o ka lawelawe waha, ua hoʻopili piha ʻia ka gliclazide mai ka ʻeha gastrointestinal. ʻAʻohe ʻai i ka ʻai ʻana. Ke hoʻonui mālie nei ka ʻike ʻana o ka mea hana i ka plasma koko, a hiki i ka nui a hiki i ka pā poli 6-12 mau hola ma hope o ka lawe ʻana i ka lāʻau. He haʻahaʻa loa ka ʻano o ka wae ʻana. ʻO ka pilina ma waena o ke ʻano a me ka neʻe o ka lāʻau lapaʻau ma ka kaila koko he linear hilinaʻi i ka manawa i ka manawa.

ʻO kahi kamaʻilio me nā protein plasma e pili ana i ka 95%.

Hoʻonohonohoʻia ia i loko o ka ate a hoʻopili i ka nui o nā keiki. Lawe ʻia ka hana e nā keiki ma ke ʻano o ka metabolites, ʻoi aku ka liʻiliʻi o 1% o ka lāʻau i ka excreted i loli ʻole.

ʻAʻohe huahana metabolites ikaika i loko o ka plasma. ʻO ka hapalua ola e like me 16 hola (12 i 20 mau hola).

I ka poʻeʻelemakule, ʻaʻohe i nānā ʻia nā hoʻololi koʻikoʻi i loko o nā pānaʻi pharmacokinetic.

ʻO ka Diabetalong® ka mea haʻomaʻi hypoglycemic waha, kahi derphative sulfonylurea o ka lua o ka hanauna.

Hoʻonui ia i ka mea huna o ka insulin i ka pancreas, hoʻohaʻahaʻa i ka pae o kaʻae i loko o ke koko, hoʻonui i ka hopena o ka insulin-secretory o ka glucose a hoʻonui i ka paʻakikī o nā ʻiʻo peripheral i ka insulin. Ma hope o 2 mau makahiki o ka mālama ʻana, ʻaʻole nui ka poʻe maʻi e hoʻomohala i ka lāʻau (hoʻonui i nā pae o ka insulin postprandial a me ka huni ʻana o C-peptides i noho).

Hoʻololi i ka manawa manawa mai ka manawa o ka ʻai ʻana a i ka hoʻomaka ʻana i ka huna ʻana i ka insulin. Hoʻihoʻi hou i ka makamua o ka loaʻa ʻana o ka inikua o ka insulin i ka pane ʻana i ka intake glucose (like ʻole me nā derivatives sulfonylurea ʻē aʻe, he hopena nui ia ma ka lua o ke ʻano o ka honi ʻana). Hoʻonui ʻia ia i ka lua o ka neʻe o ka hana huna o ka insulin. Hoʻemi i ka punaha o ka hyperglycemia ma hope o ka ʻai ʻana (a hoʻemi i ka hyperglycemia postprandial).

Hoʻonui ʻo Glyclazide i ka mahele o ke kino peripheral i insulin (i.e., he hopena i hoʻihoʻi ʻia i ka extrapancreatic). I ka kiko o ka ʻiʻo, ka hopena o ka insulin i ka uptake glucose, ma muli o ka hoʻomaikaʻi ʻana o ke ʻano maʻi i ka insulin, i hoʻonui nui ʻia (a i + 35%), ʻoiai ka mea e hoʻoulu ai ka glycazide i ka hana o ka glycogen synthetase.

Hoʻēmi i ka hana o ka glucose i loko o ka ate, ka hoʻomaʻamaʻa ʻana i nā kūlā glucose wikiwiki.

Hoʻopili i nā mea pili i ka metabolism, hiki ke hoʻonui ka gliclazide i ka microcirculation. Ke hōʻemi nei ka lāʻau lapaʻau i ka hopena o ka thrombosis liʻiliʻi, ke hoʻoikaika i nā hana ʻelua e komo ai i ka hoʻomohala ʻana o ka hoʻopiʻi i ka maʻi mellitus. hana viva endothelial a me ka hana he nui o ka kiko o ka plasminogen kiko hana.

Loaʻa i ka Glyclazide nā mea antioxidant: e hōʻemi ana i ka pae o lipid peroxides i loko o ka plasma, e hoʻonui ai i ka hana o ke kaila o ke koko reddroid dismutase.

Ma muli o nā mea kakaʻina o ka ʻano dosage, ʻo kahi papa i ka lā i kēlā me kēia lā o ka papa Diabetalong® 30 mg e hāʻawi ana i ka hopena therapeutic koʻikoʻi o gliclazide i loko o ke koko koko no 24 mau hola.

Hōʻike, hoʻokuʻu i ke ʻano

Loaʻa ka maʻi Diabetalong i ke ʻano o nā papa keʻokeʻo poepoe. Hoʻopaʻa ʻia lākou ma nā alapine o 10 mau ʻāpana a me kahi pahu pahu, kahi e hiki ai i nā 3 a 6 mau papa.

Loaʻa ka lāʻau lapaʻau i ʻelua mau huina: 30 mg a me 60 mg o ka mea hana, kahi gliclazide.

Nā mea kōkua o ka lāʻau lapaʻau.

• colloidal silicon dioxide,
• laktosa lactose,
• kaleka kaʻaila
• ʻO nā pyromellose
• ka leʻaleʻa talcum.

ʻO ke ʻano dosage paha i ke ʻano o nā papa me ka hoʻokuʻu ʻia a i ʻole ka lōʻihi.

Pharmacology a me ka pharmacokinetics

ʻO ka mea hana nui he gliclazide, ma ke ʻano kūlohelohe he mea hohonui ia o ka lua o ka hanauna sulfonylurea. Hōʻike ka Gliclazide i kahi hana koho koho kiʻekiʻe a me ka bioavailability.

He kūpaʻa ia i nā ʻano ʻolaola kūwaho a loaʻa nā hopena penei:

• hoʻonui i ka hana o ka insulin ponoʻī, e ʻae iā ʻoe e hōʻemi i ka nui o ka hormone i hoʻopaʻa ʻia,
• kaoele
• hoʻonui i ka hana o nā pehu beta pancreatic,
• ho'ēmi i ka platelet fusion, ka mea e pale ai i ka thrombosis a me nā ala ʻē aʻe vascular.

Hoʻopili piha ʻia ka maʻi diabetes ma hope o ka hoʻokele ʻana. Hōʻiliʻili pinepine i loko o ke koko, e hōʻea i kahi kaila nui o nā hola 4-6 ma hope o ka hoʻokele ʻana, e hōʻike ana i kona hopena no nā hola 10-12, a laila e emi loa ka hoʻokaʻawale ʻana o ke ʻano a ma hope o 12 mau hola i hoʻopau ʻia ai ka lāʻau mai ke kino.

Hoʻopili ʻia ka Gliclazide i ka nui o ka ʻā ʻana, a hana ʻia e nā keiki.

Nā hōʻailona a me nā contraindications

ʻO ke kumu no ka lawe ʻana i ka maʻi Diabetalong ka maʻi maʻi o ka mea maʻi - type 2 type diabetes. Hāʻawi ʻia ka lāʻau lapaʻau i hoʻohaʻahaʻa i ka hoʻokahe koko i ka wā i kūpono ʻole i nā mea paʻa i ʻōlelo ʻia ʻole.

Eia kekahi, ʻo ka lāʻau lapaʻau ka mea i koho ʻia ma ka prophylactic no nā pilikia i hōʻeha ʻia e ka maʻi mellitus, i hoʻololi nui ʻia i ke ʻano o nā kīʻaha koko ma lalo o ke ʻano o ka glycemia kiʻekiʻe.

Aia nā contraindications no ka lāʻau lapaʻau, ua komo lākou:

• maʻi diabetes type 1
• lawe ʻia
• hōʻeha maʻi nui a me ka renal maikaʻi ʻole,
• ka wā hapai a me ka umauma.
• ka heleʻana o ka ketoacidosis maʻi, coma a precoma paha,
• ka makaʻala loa i nā ʻāpana i hana i ka lāʻau lapaʻau,
• kuʻe o ka lactose metabolism,
• makahiki i ka wā ʻelemakule.

ʻO ka mālama a ma lalo o ka mākaʻi o ke kauka, hoʻohana ʻia ka lāʻau lapaʻau:

• i loko o ʻelemakule
• kanaka ʻai kino ʻole ko lākou ʻai,
• nā mea maʻi me nā luʻi cardiovascular,
• nā mea maʻi e loaʻa ana mai ka glucose-6-phosphate dehydrogenase nele,
• ma hope o ka hoʻomaloka ʻana o ka maʻi glucocorticosteroid,
• mea inu wai hoʻohālikelike
• ka loaʻa ʻana o ka pūpū a me ka ʻiole ʻole.

I kēia hihia, pono ke kauka e hoʻoholo i ke koho e pili ana i ka ʻike i ʻike.

Nā wikiō wikiō mai nā lāʻau lapaʻau:

Nā ʻōkuhi no ka hoʻohana

Hoʻololi ʻia ka nui o ka maʻi a me ka pinepine o ka hoʻohana ʻana iā Diabetalong e ke kauka, ke hilinaʻi nei lākou i nā ʻano kumuhana o ka mea maʻi a hiki ke hoʻololi maoli i kēlā me kēia kanaka.Wahi a nā ʻōlelo kuhikuhi, e lawe ʻia ana ka hoʻokipa 1-2 mau manawa i kahi lā no 20 mau minuke ma mua o ka papaʻaina. Hiki i kēia ʻano hana ke hoʻohana i ka hoʻohana pono ʻana i nā waiwai o gliclazide.

Lawe ʻia ka lāʻau ma ke alo a holoi ʻia me ka wai liʻiliʻi. Hoʻoholo ʻia ka ʻ bylelo e ke ʻano koho. I kēia hihia, pono ʻoe e hoʻomaka me 30 mg i kēlā me kēia lā, inā ʻaʻohe hopena therapeutic, e hoʻonui iki ʻia ka dosage he 30 mg a 120 mg. ʻO ka loa kēia o ka laahi i manaʻo ʻia ʻole ʻia.

ʻAʻole hiki iā ʻoe ke ʻokoʻa i ka hoʻonui ʻana i ka dosage inā ua hala kekahi o nā ʻano, ʻoiai ke alakaʻi nei ka lāʻau i ka emi ʻana o ke kō koko, hiki iā lākou ke alakaʻi i ka hypoglycemia.

ʻO nā maʻi maʻi kūikawā

No nā poʻe kahiko ma mua o 65, e koi ʻia kahi hoʻoponopono ʻana. Ma keʻano holoʻokoʻa, hoʻohanaʻia ka lāʻau lapaʻau e like me nā kānāwai like.

I loko o ka wā o ka gestation, ke kauoha ʻia nei ka lāʻau e kahuli ʻia e ka inika insulin a hiki i ka lawe ʻana. ʻAʻoheʻike me ka hoʻohana ʻana o ka maʻi Diabetalong a me nā lāʻau lapaʻau hou o ka glycoside i ka wā hāpai, no laila hiki ʻole ke hoʻoholo i kona hopena ma ka ʻōpio.

I ka wā lactation, ʻaʻole hiki ke hoʻohana ʻia ka lāʻau lapaʻau, no ka mea he hiki ke hoʻomohala i ka hypoglycemia neonatal i loko o ke keiki. No laila, pāpā ʻia ka wahine maʻi maʻi.

ʻO nā mea maʻi me ka hala ʻole ʻana a me nā ala āpau e pono e hoʻopili i nā mea haʻahaʻa, ʻo ka mea nui loa, e kiaʻi mau ʻia e ke kauka hele mai.

Hoʻopili me nā lāʻau lapaʻau ʻē aʻe

Hoʻopau ikaika ʻo Diabetalong me nā mea he nui, no laila ma mua o ka hoʻomaka ʻana o ka lawe ʻana, pono ʻoe e hoʻomaʻamaʻa iā ʻoe iho me kēia ʻano.

No laila, inā ma kahi o ka lawelawe like ʻana:

• me ka waiʻona e hiki ai i ka hypoglycemia,
• me Danazol, ua hōʻike ʻia kahi hopena maʻi maʻi, e hoʻemi ana i ka hopena o ka lāʻau lapaʻau,
• me ka miconazole, ua hoʻonui ʻia ka hopena o ka gliclazide, hiki iā ia ke hāʻawi i ka hoʻokumu o hypoglycemia, hana like me nā mea ʻē aʻe hypoglycemic,
• me ka chlorpromazine, e hoʻemi ana i ka hana o ka insulin, ke hoʻemi nui nei ka hopena o ka lāʻau lapaʻau,
• me ka tetracosactide a me glucocorticosteroids hiki ke alakaʻi i ka hoʻomohalaʻana i ka ketoacidosis a me kahi hoʻohaʻahaʻa i ka kāohi kalepa.
• me Wafarin a me nā coagulants e hoʻonui i kona hopena.

Hōʻike nā loea o nā kauka he mea maikaʻi loa ka Diabetalong i ka hoʻohaʻahaʻa ʻana i ke kaʻe o ke koko, eia nō naʻe, ʻaʻole hiki ke hoʻohana mau ʻia.

I kēia hihia, ua kuhikuhi ʻia nā ʻano o nā maʻi Diabetalong, he nui ka nui:

Hoʻomaka ʻia ke Diabetalong a me Diabeton ma ke kumu o ka lako hana like ʻole, akā ʻo ke kīloi hou ke manaʻo ʻia ʻoi aku ka maikaʻi, no ka mea, ʻoi ka hopena o kāna hana he wikiwiki, akā ʻo ke kumukūʻai o kēia lāʻau lapaʻau he 2 mau manawa kiʻekiʻe aʻe. ʻO Glyclazide kahi kikowaena kokoke loa.

Loaʻa ka lōʻihi o ka Glucophage i ka metformin i ka hoʻopili ʻana a hiki ke hoʻohui pū me ka insulin a me nā lāʻau ʻē aʻe e hoʻohaʻahaʻa i ke kahe koko.